Organigram Global Inc. (NASDAQ:OGI) confirmed Thursday a private placement investment worth 65.2 million Canadian dollars from a subsidiary of British American Tobacco (NYSE:BTI). The financing bolsters Organigram’s balance sheet and highlights BAT’s ongoing support for its Sanity Group acquisition.

Details of the deal show BAT’s unit subscribing to 14,027,074 common shares at 3.00 Canadian dollars apiece, generating 42.08 million Canadian dollars. It also exercises top-up rights for 9,897,356 shares at 2.335854 Canadian dollars each, adding 23.12 million Canadian dollars. Gross proceeds total 65.2 million Canadian dollars.

Organigram disclosed advanced talks for this exact investment on Wednesday. The confirmation arrived during Thursday’s premarket session, sending shares up 8.7% to $1.50, according to trading data.

BAT, already a shareholder in Organigram and Sanity, strengthens its stake through this move. Company executives view the investment as validation for creating a global pure-play cannabis platform with deeper reach into European markets like Germany.

Organigram’s stock sits 4.8% above its 20-day simple moving average but 6.2% below the 100-day average. That points to recent gains amid broader pressures. Over the past year, shares rose 4.55%. They trade nearer 52-week lows than highs.

Technical indicators paint a mixed picture. The relative strength index stands at 41.29, in neutral range. The MACD line rests at -0.0919, under its signal line of -0.0735, hinting at bearish momentum. Traders eye resistance at $2.00 and support at $1.50 for clues on direction.

Analysts project Organigram’s next earnings report on May 11, 2026. Expectations call for a per-share loss of 1 Canadian cent, improved from 22 cents a year earlier. Revenue should hit $54.67 million, up from $45.70 million. The stock’s price-to-earnings ratio of 12.2 times suggests potential value.

The Sanity deal positions Organigram for growth in Europe’s cannabis sector. BAT’s funding provides firepower to close the transaction and pursue expansion. Shares have shown volatility, but this capital infusion could steady the path forward.

Organigram operates as a licensed producer in Canada, focusing on recreational, medical and international cannabis markets. BAT entered the cannabis space years ago through investments like this one.